[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360714-105":59,"doc-detail-360714-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","application-of-percutaneous-cryoablation-for-pulmonary-nodules-and-influence-in-pulmonary-function","Application of percutaneous cryoablation for pulmonary nodules and influence in pulmonary function","","Cryoablation is evaluated as a non-surgical option for early-stage lung cancer and a palliative therapy for advanced disease and pulmonary metastases, though existing evidence remains limited. A retrospective study of 94 patients (107 pulmonary nodules) receiving CT-guided percutaneous cryoablation from May 2022 to May 2024 compares curative-intent and palliative-intent groups. Local control and survival outcomes are assessed alongside pulmonary function changes and adverse events. Cryoablation shows high local control rates, preserved pulmonary function, and defines key safety considerations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/application-of-percutaneous-cryoablation-for-pulmonary-nodules-and-influence-in-pulmonary-function/360714/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/application-of-percutaneous-cryoablation-for-pulmonary-nodules-and-influence-in-pulmonary-function/360714.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this study on percutaneous cryoablation?","Question",{"text":112,"@type":113},"To evaluate efficacy and safety of cryoablation across different types of pulmonary nodules and to identify appropriate clinical scenarios for its use.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and how were patients grouped?",{"text":117,"@type":113},"A retrospective cohort of 94 patients with 107 pulmonary nodules underwent CT-guided percutaneous cryoablation between May 2022 and May 2024. Patients were classified into curative-intent and palliative-intent groups, with additional subgroups within the curative group.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding local control, recurrence, and pulmonary function?",{"text":121,"@type":113},"Cryoablation achieved 100% local control in pure ground-glass nodules, with some recurrence in part-solid and solid nodules. In solitary pulmonary nodules/sMPN and second primary lung cancer subsets, outcomes varied, while pulmonary function showed no significant deterioration after treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360714,1790734055,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Tian et al. BMC Cancer (2026) 26:803 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15929-z](https://doi.org/10.1186/s12885-026-15929-z)  \nRESEARCH Open Access  \nApplication of percutaneous cryoablation for pulmonary nodules and influence in pulmonary function  \nHuohuan Tian1,2,3†, Yue Cheng1,3†, Dan Li1,3†, Rao Du1,2,3,4†, Kaige Wang1,3, Hongli Bai4, Wanxin Liang1,2,3, Jue Li2,3, Weimin Li 1,2,3 and Dan Liu 1,2,3*  \nAbstract  \nBackground Cryoablation has been reported as a non-surgical option for early-stage lung cancer and a palliative cytoreductive therapy for advanced disease and pulmonary metastases; however, evidence remains relatively limited. Purpose To evaluate the efficacy and safety of cryoablation in patients with different types of pulmonary nodules and to identify appropriate clinical scenarios for its application.  \nMethod This retrospective study included 94 patients with 107 pulmonary nodules who underwent CT-guided percutaneous cryoablation between May 2022 and May 2024. Patients were classified into curative-intent (early-stage lung cancer) and palliative-intent (advanced/recurrent lung cancer or pulmonary metastases) groups. The curative group was further subdivided into solitary pulmonary nodules, synchronous multiple primary nodules (sMPN), and second primary lung cancer (SPLC) . Primary outcomes were local recurrence-free survival (LRFS) and recurrence-free survival (RFS) in the curative group, and progression-free survival (PFS) in the palliative group. Secondary outcomes included residual nodule progression in sMPN patients, pulmonary function changes and adverse events.  \nResult Seventy-three patients with 86 nodules received curative treatment, and 21 patients received palliative treatment. Cryoablation achieved 100% local control in pure ground-glass nodules (pGGNs), while local recurrence occurred in one part-solid and two solid nodules. Among 22 patients with sMPN, all the patients showed 100% LRFS and RFS, regardless of whether they received combined surgery and cryoablation or cryoablation alone. In 15 patients with SPLC, local control was 100%, but three developed recurrence or metastasis outside the ablation zone. The median PFS in the palliative group was 409 days. Pulmonary function did not show significant deterioration after cryoablation. Pneumothorax and hemoptysis were the most common adverse events (21 .4% each), with a fatal complication rate of 0 . 9% .  \n†Huohuan Tian, Yue Cheng, Dan Li and Rao Du contributed equally to this work.  \n*Correspondence: Dan Liu [liudan10965@wchscu.cn](liudan10965@wchscu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nTian et al. BMC Cancer (2026) 26:803 Page 2 of 14  \nConclusion Cryoablation preserves pulmonary function and may benefit patients ineligible for surgery. It may serve as a treatment op","cbCailBjwLkrIiHH","https://ap.wps.com/l/cbCailBjwLkrIiHH","pdf",3189827,14,"English","# Abstract\n# Background\n# Purpose\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What was the purpose of this study on percutaneous cryoablation?\",\"answer\":\"To evaluate efficacy and safety of cryoablation across different types of pulmonary nodules and to identify appropriate clinical scenarios for its use.\"},{\"question\":\"How was the study conducted and how were patients grouped?\",\"answer\":\"A retrospective cohort of 94 patients with 107 pulmonary nodules underwent CT-guided percutaneous cryoablation between May 2022 and May 2024. Patients were classified into curative-intent and palliative-intent groups, with additional subgroups within the curative group.\"},{\"question\":\"What were the main findings regarding local control, recurrence, and pulmonary function?\",\"answer\":\"Cryoablation achieved 100% local control in pure ground-glass nodules, with some recurrence in part-solid and solid nodules. In solitary pulmonary nodules/sMPN and second primary lung cancer subsets, outcomes varied, while pulmonary function showed no significant deterioration after treatment.\"}]","Application of percutaneous cryoablation for pulmonary nodules and influence in pulmonary function | PDF",1790141303,35]